BFS
MRKR icon

Boyer Financial Services’s Marker Therapeutics MRKR Stock Holding History

Boyer Financial Services’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,817
Closed -$56.7K – 50
2025
Q4 		$56.7K Buy
+36,817
New +$41.7K 0.06% 47

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Boyer Financial Services's MRKR Position: Q1 2026 in Review

Boyer Financial Services sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 36,817 shares — an estimated $56.7K sold.

Boyer Financial Services first reported a position in MRKR in Q4 2025 and held it in 1 quarter. The position peaked at $56.7K in Q4 2025. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Boyer Financial Services reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Boyer Financial Services sold 36,817 Marker Therapeutics shares in Q1 2026, an estimated $56.7K.
  • Boyer Financial Services first reported a position in Marker Therapeutics in Q4 2025 and held it in 1 quarter.
  • Boyer Financial Services's Marker Therapeutics position peaked at $56.7K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Boyer Financial Services's 13F filing for Q1 2026, filed 10 Apr 2026.